StreetInsider.com News Articles

Wells Fargo Starts X4 Pharmaceuticals (XFOR) at Overweight

Fri, 10 Jul 2026 05:44:00 -0400

(Updated - July 10, 2026 5:44 AM EDT)

Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ: XFOR) with a Overweight rating and a price target of $11.00.

The analyst comments "We believe the Street is materially underestimating the probability of Ph3 success for mavorixafor in chronic neutropenia, creating an attractive risk/reward ahead of the 2H27 readout. Our base case implies approximately ~3x upside. Mavorixafor is being developed in CN and is approved in WHIM. While approved in WHIM, the company has deprioritized the launch given how small the indication is, making CN the key value driver for mavor. We

Wells Fargo Starts X4 Pharmaceuticals (XFOR) at Overweight

Fri, 10 Jul 2026 05:44:00 -0400

(Updated - July 10, 2026 5:44 AM EDT)

Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ: XFOR) with a Overweight rating and a price target of $11.00.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 07 Jul 2026 16:30:00 -0400

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 750,000 shares of X4’s common

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 07 Jul 2026 16:30:00 -0400

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 07 Jul 2026 16:30:00 -0400

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 07 Jul 2026 16:30:00 -0400

Form 4 X4 Pharmaceuticals, Inc For: Jun 30 Filed by: KIRSKE DAVID

Wed, 01 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260701/26721064.html

Form 4 X4 Pharmaceuticals, Inc For: Jun 30 Filed by: KIRSKE DAVID

Wed, 01 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260701/26721064.html

Form 4 X4 Pharmaceuticals, Inc For: Jul 01 Filed by: Gold Kelly

Wed, 01 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26721001.html

Form 4 X4 Pharmaceuticals, Inc For: Jul 01 Filed by: Gold Kelly

Wed, 01 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26721001.html

Form 3 X4 Pharmaceuticals, Inc For: Jul 01 Filed by: Gold Kelly

Wed, 01 Jul 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260701/26720966.html

Form 3 X4 Pharmaceuticals, Inc For: Jul 01 Filed by: Gold Kelly

Wed, 01 Jul 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260701/26720966.html

Form 8-K X4 Pharmaceuticals, Inc For: Jun 30

Wed, 01 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260701/26720786.html

Form 8-K X4 Pharmaceuticals, Inc For: Jun 30

Wed, 01 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260701/26720786.html

X4 Pharmaceuticals adds Kelly Gold to its board of directors

Wed, 01 Jul 2026 07:00:39 -0400

X4 Pharmaceuticals (Nasdaq: XFOR) announced the appointment of Kelly Gold to its board of directors, effective July 1, 2026. Gold will serve as an independent director and member of the Audit Committee, according to a press release from the company.

Gold currently serves as Chief Financial Officer at CAMP4 Therapeutics (Nasdaq: CAMP), where she oversees corporate finance and accounting, investor relations, and strategic financial planning. Before becoming CFO at CAMP4, she held roles in business development and finance at the same company.